UNSPSC 51321604: Polidocanol

This classification denotes a tissue adhesive, detergent, and sclerosing solution with the molecular formula C12H26O(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0AWH8BFG9A, chemically known as 3,6,9,12,15,18,21,24,27-nonaoxanonatriacontan-1-ol but generally known as polidocanol, which bears US NIH Compound Identifier 24750. European Medicines Agency schedules Polidocanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03917MIG.

World Health Organization schedules polidocanol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, POLIDOCANOL remains the US FDA Preferred Term for this commodity. SMILES: O(CCCCCCCCCCCC)CCO.

UNSPSC 51321604 Polidocanol, a Commodity code, covers pharmaceutical supply procurement for emergency medical services, public health programs, and institutional care facilities. State and local governments use this code to acquire specific injectable medications and pharmaceutical products for first-responder use, pharmacy benefit programs, and multi-jurisdiction cooperative purchasing. The code applies to sealed-bid and RFP solicitations for branded and generic pharmaceuticals, with vendors required to meet expiration-dating standards, supply-chain security certifications, FDA compliance, and chain-of-custody documentation including Safety Data Sheets and accessibility conformance reports.

Recent activity shows procurement from city fire departments, state health agencies, and multi-state cooperative purchasing alliances. The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188, due April 8, 2026) for Tampa Fire Rescue, requiring 370 units of Labetalol HCI, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg, with a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount capped at $10,000 and an estimated contract value of $40,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring cGMP and Drug Supply Chain Security Act certification and distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013, April 3, 2026) regarding direct-to-manufacturer pharmacy benefit strategies. Recent opportunities concentrate in the upper Midwest and South, with solicitation timelines typically spanning 30–60 days from posting to response deadline, firm pricing and supply requirements, and performance warranties extending 12 months or longer.